A Study of Tarceva (Erlotinib) Monotherapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT01996332 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

1805

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: erlotinib [Tarceva]

Sponsor

Hoffmann-La Roche